Ascendis Pharma Files December 2025 6-K Report
Ticker: ASND · Form: 6-K · Filed: Dec 30, 2025 · CIK: 1612042
| Field | Detail |
|---|---|
| Company | Ascendis Pharma A/S (ASND) |
| Form Type | 6-K |
| Filed Date | Dec 30, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $63.34 |
| Sentiment | neutral |
Sentiment: neutral
Topics: reporting, sec-filing, foreign-private-issuer
TL;DR
Ascendis Pharma (ASND) filed its monthly 6-K report on Dec 30, 2025, standard compliance filing.
AI Summary
Ascendis Pharma A/S, a pharmaceutical company, filed a Form 6-K on December 30, 2025. This report is for the month of December 2025 and is being filed under the Securities Exchange Act of 1934. The company is incorporated in G7 and its fiscal year ends on December 31st. Its principal executive offices are located in Hellerup, Denmark.
Why It Matters
This filing indicates Ascendis Pharma A/S is complying with its reporting obligations as a foreign private issuer, providing routine updates to the SEC.
Risk Assessment
Risk Level: low — This is a routine filing for a foreign private issuer and does not contain new material financial information or strategic changes.
Key Numbers
- 1231 — Fiscal Year End (Indicates the company's financial year concludes on December 31st.)
- 20251230 — Filing Date (The date the Form 6-K was officially submitted to the SEC.)
Key Players & Entities
- Ascendis Pharma A/S (company) — Registrant
- 001-36815 (company) — SEC File Number
- 333-203040, 333 (company) — Form S-8 Registration Numbers
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers pursuant to Section 13a-16 or 15d-16 under the Securities Exchange Act of 1934, used to furnish information which the issuer would be required to make public pursuant to the laws of its home country or which it may otherwise make or has made public.
What is Ascendis Pharma A/S's fiscal year end?
Ascendis Pharma A/S's fiscal year ends on December 31st.
Where are Ascendis Pharma A/S's principal executive offices located?
Ascendis Pharma A/S's principal executive offices are located at Tuborg Boulevard 12, DK-2900 Hellerup, Denmark.
Under which SEC Act is this Form 6-K filed?
This Form 6-K is filed under the Securities Exchange Act of 1934.
Does Ascendis Pharma A/S file an annual report on Form 20-F or 40-F?
Ascendis Pharma A/S indicates it files annual reports under cover of Form 20-F.
Filing Stats: 396 words · 2 min read · ~1 pages · Grade level 15.9 · Accepted 2025-12-30 16:15:13
Key Financial Figures
- $63.34 — cash consideration of approximately USD $63.34 per share, based on the DKK-USD exchang
Filing Documents
- d214993d6k.htm (6-K) — 12KB
- d214993dex11.htm (EX-1.1) — 1205KB
- g214993dsp174.jpg (GRAPHIC) — 3KB
- g214993dsp175.jpg (GRAPHIC) — 3KB
- g214993dsp177.jpg (GRAPHIC) — 3KB
- g214993dsp178.jpg (GRAPHIC) — 3KB
- g214993dsp179.jpg (GRAPHIC) — 3KB
- g214993dsp180.jpg (GRAPHIC) — 5KB
- g214993dsp_24a.jpg (GRAPHIC) — 4KB
- g214993dsp_25a.jpg (GRAPHIC) — 8KB
- g214993dsp_25b.jpg (GRAPHIC) — 3KB
- g214993dsp_26a.jpg (GRAPHIC) — 6KB
- g214993dsp_33a.jpg (GRAPHIC) — 4KB
- g214993dsp_33b.jpg (GRAPHIC) — 8KB
- g214993dsp_34a.jpg (GRAPHIC) — 3KB
- g214993dsp_34b.jpg (GRAPHIC) — 6KB
- g214993page43.jpg (GRAPHIC) — 4KB
- g214993page44a.jpg (GRAPHIC) — 8KB
- g214993page44b.jpg (GRAPHIC) — 3KB
- g214993page45.jpg (GRAPHIC) — 6KB
- 0001193125-25-337124.txt ( ) — 1338KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Ascendis Pharma A/S Date: December 30, 2025 By: /s/ Michael Wolff Jensen Michael Wolff Jensen Executive Vice President, Chief Legal Officer